Athira Pharma (ATHA)
(Real Time Quote from BATS)
$1.98 USD
-0.03 (-1.49%)
Updated Apr 25, 2024 11:12 AM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATHA 1.98 -0.03(-1.49%)
Will ATHA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ATHA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATHA
Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?
Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?
ATHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy?
All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy
Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA)
Other News for ATHA
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Athira Pharma appoints Javier San Martin as Chief Medical Officer
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Athira Pharma announces publication of preclinical data on fosgonimeton
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting